Markets
MarketMind AI
Baskets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
Financials
Charts & Report
Charts and Graphs
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Price History/Seasonality
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
IPO
Alerts
About
Alivus Life Sciences Ltd.
NSE: ALIVUS
|
BSE: 543322
|
ISIN: INE03Q201024
|
Industry: Pharmaceuticals
|
Strong Performer, Getting Expensive
1055.5000
-14.80
(
-1.38
%)
NSE
May 29, 2026
15:31 PM
28.88% Gain from 52W Low
Volume:
60,799
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Alivus Life Sciences Ltd.
22 Jul 2023
1055.50
-1.38%
Glenmark Life Sciences (HOLD): Another good quarter; cut to HOLD post rally
Hold:
Alivus Life Sciences Ltd.
by
BOB Capital Markets Ltd.
Target: 620
Recommendation
Target
BOB Capital Markets Ltd.
Strong Q1 with EBITDA/PAT beat of 10%/6% despite slight miss on revenue
Alivus Life Sciences.. has an
average target
of 1235.00 from 1 broker.
More from Alivus Life Sciences Ltd.
Recommended
Five Interesting Stocks Today - May 29, 2026
The Baseline |
29 May 2026, 05:21PM
Market closes lower amid US-Iran deal uncertainty and foreign fund outflows
Trendlyne Marketwatch |
29 May 2026, 03:59PM
Glenmark Life Sciences: The hived off API business of Glenmark Pharma goes public
|
27 Jul 2021